JR Vyas, CMD, Dishman Pharma in an interview to CNBC-TV18 clarified that the company had not received any warning from US FDA on Clovis issue.
first published: Nov 18, 2015 09:59 am
A collection of the most-viewed Moneycontrol videos.
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
Canara Robeco AMC's Rs 1326 Cr IPO Kicks Off | Management Shares Growth Plans| IPO Watch Live
Live: Can Nifty hold above 25,000 as TCS begins Q2 results | Opening Bell
You are already a Moneycontrol Pro user.